Brontictuzumab
Based on 1 Customer Validation
Brontictuzumab (OMP 52M51) is a monoclonal antibody (MAb) that inhibits Notch1 signal. Brontictuzumab selectively binds the negative regulatory region of the Notch1. Brontictuzumab inhibits tumor cell proliferation. Brontictuzumab can be used in the research of leukemia and lymphoma.
For research use only. We do not sell to patients.
- Purity: 95.00%
- CAS No.: 1447814-75-6
- Molecular Weight:150 kDa
-
Storage:
Please store the product under the recommended conditions in the Certificate of Analysis.
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Biological Activity
-
Chemical Information
- Purity & Documentation
- References
-
Help & FAQs
Biological Activity
Human IgG2 lambda
Human
NOTCH1
Brontictuzumab (0-100 μg/mL) inhibits Notch1 signaling, including DLL4, JAG1/2 activity[1].
Brontictuzumab (25 μg/mL, 4 days) reduces the levels of Notch1 intracellular domain in the HPB-ALL cell line[1].
Brontictuzumab (25 μg/mL, 48 h) inhibits DLL4-mediated cleaved-Notch1 overexpression in MCL cells[2].
Brontictuzumab (25 μg/mL, 48 h) blocks the increased phosphorylation of both, MEK and ERK by DLL4 stimulation in Mino cells[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:DLL4 (4 μg/mL)-stimulated MCL cells
-
Concentration:25 μg/mL
-
Incubation Time:24 or 48 h
-
Result:Inhibited DLL4-dependent activation of Notch1.
Brontictuzumab (20 mg/kg, i.p., every 4 days) inhibits DLL4 induced activation of Notch1 in MCL model[2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:T-ALL xenograft[3]
-
Dosage:15 mg/kg
-
Administration:Intraperitoneal injection (i.p.), twice weekly.
-
Result:Inhibited tumor growth and reduced the size of the spleen.
Showed massive infiltration and replacement of normal hematopoiesis by leukemia cells.
-
Animal Model:NSG mice injected with DLL4-stimulated NOTCH1-mutated mino cells ex vivo[2]
-
Dosage:20 mg/kg
-
Administration:Intraperitoneal injection (i.p.)
-
Result:Inhibited cleaved Notch1 but was not enough to cause a significant efficacy in tumor growth.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Unconjugated
The product can be reconstituted/diluted with sterile PBS or saline.
-
Human IgG2 lambda
ELISA, FACS, Functional assay
-
Flow cytometric analysis of 1X106 Jurkat cells labeling Brontictuzumab (HY-P99258, red). Cells were fixed with 4% paraformaldehyde. Then stained with the primary antibody at 1/200 dilution for an hour at 4℃. Alexa Fluor488-conjugated AffiniPure Goat Anti-Human IgG H&L (HY-P83776) was used as the secondary antibody at 1/1,000 dilution for 30 minutes at 4℃. Human IgG2 lambda (HY-P991206, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (black).
Chemical Information
-
CAS No. 1447814-75-6
-
Appearance Liquid
-
Molecular Weight 150 kDa
-
Color Colorless to light yellow
-
SMILES
[Brontictuzumab]
-
Synonyms
OMP 52M51; Anti-Human NOTCH1 Recombinant Antibody
-
Shipping
Shipping with dry ice.
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Storage
Please store the product under the recommended conditions in the Certificate of Analysis.
Purity & Documentation
-
Data Sheet (261 KB)
-
SDS (252 KB)
- English - EN (252 KB)
- Français - FR (252 KB)
- Deutsch - DE (252 KB)
- Norwegian - NO (252 KB)
- Español - ES (252 KB)
- Swedish - SV (252 KB)
- Italian - IT (252 KB)
- Korean - KR (252 KB)
- Portuguese - PT (252 KB)
-
Inhibitory Antibodies User Guide (603 KB)
References
[1]. Ferrarotto R, et al. A phase I dose-escalation and dose-expansion study of brontictuzumab in subjects with selected solid tumors. Ann Oncol. 2018 Jul 1;29(7):1561-1568. [Content Brief]
[2]. Silkenstedt E, et al. Notch1 signaling in NOTCH1-mutated mantle cell lymphoma depends on Delta-Like ligand 4 and is a potential target for specific antibody therapy. J Exp Clin Cancer Res. 2019 Nov 1;38(1):446. [Content Brief]
[3]. Agnusdei V, et al. Therapeutic antibody targeting of Notch1 in T-acute lymphoblastic leukemia xenografts. Leukemia. 2014 Feb;28(2):278-88. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
Brontictuzumab Related Classifications
HY-P99258 Related Classifications
Powered by Bioz